SHR0302 + SHR0302 placebo
Phase 3UNKNOWN 2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-radiographic Axial Spondyloarthritis
Conditions
Non-radiographic Axial Spondyloarthritis
Trial Timeline
Aug 16, 2022 → Dec 11, 2024
NCT ID
NCT05324631About SHR0302 + SHR0302 placebo
SHR0302 + SHR0302 placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Non-radiographic Axial Spondyloarthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT05324631. Target conditions include Non-radiographic Axial Spondyloarthritis.
What happened to similar drugs?
1 of 3 similar drugs in Non-radiographic Axial Spondyloarthritis were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05324631 | Phase 3 | UNKNOWN |
| NCT04481139 | Phase 2/3 | Completed |
Competing Products
4 competing products in Non-radiographic Axial Spondyloarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 27 |
| Secukinumab + Placebo | Novartis | Phase 3 | 40 |
| Secukinumab + Placebo + Secukinumab | Novartis | Approved | 47 |
| Secukinumab + Placebo | Novartis | Phase 3 | 40 |